Form 4: Jasper Therapeutics' Chief Medical Officer Acquires Shares Under Employee Stock Purchase Plan

Edwin Tucker, Chief Medical Officer of Jasper Therapeutics, acquired 400 shares of voting common stock through the company's 2021 Employee Stock Purchase Plan on June 7, 2024.

Summary

• Edwin Tucker, the Chief Medical Officer of Jasper Therapeutics, acquired 400 shares of voting common stock on June 7, 2024.
• The acquisition was made through the company's 2021 Employee Stock Purchase Plan at a price of $4.1735 per share.
• This transaction is reported on a Form 4 filing with the SEC, indicating a change in beneficial ownership.
• A Power of Attorney was executed on May 29, 2024, granting Ronald Martell and Herb Cross the authority to act on behalf of Edwin Tucker for SEC filings related to company securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a routine transaction. The acquisition of shares by an executive is generally viewed positively, but this is a standard procedure.

Positives

• The acquisition of shares by a company officer can be seen as a positive sign, indicating confidence in the company's future.

Industry Context

This filing is a routine disclosure related to insider trading and is a common occurrence for publicly traded companies. It provides transparency into the transactions of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
• Companies like Amgen, Gilead, and Biogen regularly file similar forms when their executives trade company stock.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals confidence from a company executive.

Key Dates